Want to see MREO full AI Analyst Report?
MREO Stock Chart & Stats
$0.29
>-$0.01(-1.10%)
At close: 4:00 PM EDT
$0.29
>-$0.01(-1.10%)
Day’s Range― - ―
52-Week Range$0.20 - $2.37
Previous CloseN/A
Volume389.50K
Average Volume (3M)1.26M
Market Cap
$45.94M
Enterprise Value$13.26M
Total Cash (Recent Filing)$36.22M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 18, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding159,618,600
10 Day Avg. Volume647,111
30 Day Avg. Volume1,259,275
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.62
Price to Sales (P/S)132.86
P/FCF Ratio-2.14
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue26.52
Enterprise Value/Gross Profit212.10
Enterprise Value/Ebitda-0.34
Forecast
1Y Price Target
$3.00Price Target Upside934.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$2.37M
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Zero DebtThe company’s zero total debt is a durable structural strength for a clinical-stage biotech. Low leverage reduces fixed financing costs and interest sensitivity, preserving flexibility to fund trials or partner deals and lowering insolvency risk while development programs progress.
High Gross Margins On SalesReported gross margins in the low-70% range indicate favorable product economics for the revenue realized to date. If clinical successes translate to commercial sales or licensing, these structurally strong gross margins support scalable profitability once operating leverage improves.
Board Continuity & Capital FlexibilityReappointment of board members maintains governance continuity, while extended authority to allot and issue shares provides an explicit, multi-year mechanism to raise equity. That structural financing flexibility supports long-term funding of development programs and partnership negotiations.
Bears Say
Persistent Cash BurnConsistent operating and free cash outflows (~$27M TTM) are a durable weakness for a development-stage biotech. Sustained cash burn shortens runway, forces recurring financing, and raises existential risk if clinical timelines slip or fundraising conditions tighten.
Minimal Revenue, Large Net LossesCommercial traction is effectively nonexistent: revenue is immaterial while net losses are large. This structural lack of recurring income means the company remains fully dependent on external financing or milestone payments until product commercialization, increasing execution and funding risk.
Eroding Equity Base / Dilution RiskShareholders’ equity has declined materially, shrinking the firm’s capital buffer. Combined with ongoing losses and the board’s renewed authority to issue shares, this structural trend heightens dilution risk over time and reduces balance-sheet resilience during extended development cycles.
Mereo Biopharma Group Plc News
MREO FAQ
What was Mereo Biopharma Group Plc’s price range in the past 12 months?
Mereo Biopharma Group Plc lowest stock price was $0.20 and its highest was $2.37 in the past 12 months.
What is Mereo Biopharma Group Plc’s market cap?
Mereo Biopharma Group Plc’s market cap is $45.94M.
When is Mereo Biopharma Group Plc’s upcoming earnings report date?
Mereo Biopharma Group Plc’s upcoming earnings report date is Aug 18, 2026 which is in 22 days.
How were Mereo Biopharma Group Plc’s earnings last quarter?
Mereo Biopharma Group Plc released its earnings results on May 12, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of -$0.009 by -$0.001.
Is Mereo Biopharma Group Plc overvalued?
According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued.
Does Mereo Biopharma Group Plc pay dividends?
Mereo Biopharma Group Plc does not currently pay dividends.
What is Mereo Biopharma Group Plc’s EPS estimate?
Mereo Biopharma Group Plc’s EPS estimate is >-0.01.
How many shares outstanding does Mereo Biopharma Group Plc have?
Mereo Biopharma Group Plc has 159,618,600 shares outstanding.
What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?
Mereo Biopharma Group Plc reported an EPS of -$0.01 in its last earnings report, missing expectations of -$0.009. Following the earnings report the stock price went up 1.653%.
Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?
Currently, no hedge funds are holding shares in MREO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mereo Biopharma Group Plc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (934.48% Upside)
$3.00 (934.48% Upside)
Hedge Fund Trend
Decreased
By 517.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-40.55%
Trailing 12-Months
Company Description
Mereo Biopharma Group Plc
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
MREO Stock 12 Month Forecast
Average Price Target
$3.00
▲(934.48% Upside)
Technical Analysis
Ownership Overview
0.81%
Insiders
0.09% Mutual Funds
37.27% Other Institutional Investors
61.74% Public Companies and
Individual Investors